Abstracts 493 mias. Health-care utilization and cost data for each of the two patient categories were averaged and annualized. Costs were converted from local currencies to Euros.
PCV13

EFFECT OF AMLODIPINE TREATMENT ON CARDIOVASCULAR DISEASE-RELATED HOSPITALIZATIONS AND COSTS IN PATIENTS WITH CORONARY ARTERY DISEASE IN SPAIN
OBJECTIVE:
The purpose of this study was to examine the effect of amlodipine treatment on cardiovascular disease (CVD) related hospital admissions and the corresponding costs in patients with coronary artery disease (CAD) in Spain. METHODS: This analysis used data from Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT), a double-blind, randomized, placebo-controlled, multi-center clinical trial. A decisiontree model was used to analyze the expected incremental cost of amlodipine treatment relative to placebo. A sensitivity analysis was conducted to examine the robustness of the study outcome. The hospital costs were estimated using the DRG's from the Medicare adjusted to the median of a local hospital stay cost (Catalonian area). RESULTS: Amlodipine significantly reduced the number of CVD-related hospital admissions and procedures in patients with CAD relative to placebo. The expected CVDrelated hospital cost per patient in the placebo group exceeded costs for patients in the amlodipine group. The expected savings of CVD-related hospitalizations ranged from 0 to 331 Euros per patient over the trial period in 1997 Spanish pesetas when the cost to charge ratio was changed from 0.66 to 1.2. The total expected costs for the amlodipine group were 1,723.5 Euros (533 for no CVD hospitalization and 1190 for CVD hospitalization) while the total expected costs for the placebo group were 1929 Euros (119 for No CVD hospitalization and 1810 for CVD hospitalization). At the breakeven point (the cost to charge ratio ϭ 0.66), the amlodipine treatment still offset the drug cost of amlodipine.
CONCLUSIONS:
Use of amlodipine can reduce CVDrelated hospital admissions and associated costs in patients with coronary artery disease. Amlodipine is a costsaving agent in the treatment of patients with coronary artery disease. 
PCV14
COST-OF-ILLNESS STUDY OF UNSTABLE ANGINA PECTORIS IN GERMANY
OBJECTIVES:
To install a world-wide-web (WWW, internet) -based registry for the observation of treatment patterns for unstable Angina Pectoris (uAP) and to estimate the economic burden of uAP in Germany from the perspective of the statutory health insurance (Gesetzliche Krankenversicherung) and of hospitals as service providers. METHODS: Prospective, bottom-up, cross-sectional costof-illness (COI) study. Three hundred sixteen patients consecutively included between November 2000 and May 2001 were documented via an Internet-based registry using standardized documentation forms. Inclusion and exclusion criteria were pre-defined. Fifteen centers of different healthcare levels (10 university hospitals, 1 specialized hospital, 4 general hospitals) participated. Direct costs (for diagnostic, medical treatment, surgery, drug therapy) and indirect costs (due to lost productivity) associated with inpatient treatment due to uAP were considered. RESULTS: Mean age of patients was around 65 years for females (34%) and 69 years for males (66%). In about 99% of cases, uAP was diagnosed at hospital admission: 47% were hospitalized as emergency cases; 26% were referred from other hospitals; 26% from office-based physicians. Mean hospital stay lasts 8.3 days per patient, 6.8 days of them spent in intensive care. Angiography or angioplasty were performed on 78% of patients. About 4% of patients underwent heart surgery, most of them for triple coronary bypass. 30% of patients received one of the new platelet aggregation inhibitors (Abciximab, Eptifibatide, Tirofiban) during hospitalization. CONCLUSIONS: Because the registry is still ongoing, cost data are under evaluation, but will be finalized for poster presentation. Treatment with platelet aggregation inhibitors is still not very common, despite being recommended by German therapy guidelines for uAP treatment.
